Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors

The anti-apoptotic protein Survivin is highly expressed in Cancer cells but has a very low expression in fully differentiated adult cells. Overexpression of Survivin is positively correlated with Cancer cell resistance to chemotherapy and radiotherapy, Cancer cell metastasis, and poor patient prognosis. Therefore, selective targeting Survivin represents an attractive strategy for the development of Anticancer therapeutics. Herein, we reported the extensive structural modification of our recently discovered selective Survivin Inhibitor UC-112 and the synthesis of thirty-three new analogs. The structure-activity relationship (SAR) study indicated that replacement of the benzyloxy moeity in UC-112 with an indole moiety was preferred to other moieties. Among these UC-112 analogs, 10f, 10h, 10k, 10n showed the most potent antiproliferative activities. Interestingly, they were more potent against the P-glycoprotein overexpressing Cancer cell lines compared with the parental Cancer cell lines. Mechanistic studies confirmed that new analogs maintained their unique selectivity against Survivin among the IAP family members. In vivo study using 10f in a human A375 melanoma xenograft model revealed that it effectively inhibited melanoma tumor growth without observable acute toxicity. Collectively, this study strongly supports the further preclinical development of selective Survivin inhibitors based on the UC-112 scaffold.